Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBIT: 2017-2024

Historic EBIT for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to -$136.7 million.

  • Tonix Pharmaceuticals Holding's EBIT fell 112.59% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$136.7 million for FY2024, which is 15.48% down from last year.
  • As of FY2024, Tonix Pharmaceuticals Holding's EBIT stood at -$136.7 million, which was down 15.48% from -$118.4 million recorded in FY2023.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's EBIT peaked at -$50.5 million during FY2020, and registered a low of -$136.7 million during FY2024.
  • Its 3-year average for EBIT is -$122.4 million, with a median of -$118.4 million in 2023.
  • Data for Tonix Pharmaceuticals Holding's EBIT shows a maximum YoY slumped of 82.76% (in 2021) over the last 5 years.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's EBIT (Yearly) stood at -$50.5 million in 2020, then tumbled by 82.76% to -$92.3 million in 2021, then decreased by 21.43% to -$112.1 million in 2022, then declined by 5.61% to -$118.4 million in 2023, then declined by 15.48% to -$136.7 million in 2024.